Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals' combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine dTpa (Boostrix) when administered in healthy adult subjects, after previous booster vaccination with dTpa in study 263855/029 (dTpa-029).

Next Previous
X
Search
Trial Profile

A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals' combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine dTpa (Boostrix) when administered in healthy adult subjects, after previous booster vaccination with dTpa in study 263855/029 (dTpa-029).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline Biologicals; GSK

    • Most Recent Events

    • 16 Aug 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 30 Sep 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top